Banking's New Guard: The Apple Card Consolidation
JPMorgan Chase's potential takeover of the Apple Card from Goldman Sachs signals a major shift in high-profile financial partnerships. This theme focuses on the large-scale banks and payment processors best positioned to benefit from the growing trend of tech giants seeking established, reliable partners for their financial products.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
About This Group of Stocks
Our Expert Thinking
JPMorgan's potential Apple Card takeover represents a major shift toward established banking giants in high-profile fintech partnerships. This consolidation trend suggests tech companies are prioritizing reliability and scale over newer market entrants, creating opportunities for proven financial institutions and their technology partners.
What You Need to Know
This group includes large-scale banks, payment processors, and fintech infrastructure providers positioned to benefit from the growing demand for reliable financial partnerships. These companies have the capital, regulatory experience, and technological capabilities to handle massive co-branded credit portfolios and support tech giants' financial ambitions.
Why These Stocks
These stocks were handpicked based on their strategic positioning in the evolving landscape of tech-finance partnerships. They represent companies across the value chain - from major banks capable of managing huge credit portfolios to essential payment networks and fintech service providers that supply critical infrastructure.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+11.57%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 11.57% over the next year.
Stocks Rated Buy by Analysts
15 of 17 assets in this group are rated Buy by professional analysts.
Group Growth
This group averaged a 1.4% return last month.
Why You'll Want to Watch These Stocks
Industry Consolidation Wave
Major banks are taking over high-profile fintech partnerships, creating clear winners in the consolidation trend. This shift toward established players could drive significant value for well-positioned institutions.
Scale Advantage Pays Off
Companies with the capital and infrastructure to handle massive credit portfolios are becoming the preferred partners for tech giants. This flight to stability could reward the biggest and most reliable players.
Tech Partnership Boom
As more technology companies seek banking partners for their financial products, the demand for proven fintech infrastructure and payment processing solutions is accelerating rapidly.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.